Shopping Cart
- Remove All
Your shopping cart is currently empty
FGTI-2734 mesylate (1247018-19-4 free base)
😃Good
Catalog No. T11282LCas No. 2702297-24-1
Alias FGTI-2734 mesylate
FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.
FGTI-2734 mesylate (1247018-19-4 free base)
😃Good
Catalog No. T11282LAlias FGTI-2734 mesylateCas No. 2702297-24-1
FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 5 mg | $311 | Backorder | |
| 10 mg | $575 | Backorder | |
| 50 mg | $1,762 | Backorder | |
| 100 mg | $3,081 | Backorder | |
| 200 mg | Inquiry | Backorder | |
| 500 mg | Inquiry | Backorder | |
| 1 mL x 10 mM (in DMSO) | $414 | Backorder |
Bulk & Custom
Add to Cart
Questions
View MoreContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | FGTI-2734 mesylate, a RAS C-terminal mimetic compound with dual farnesyl transferase (FT) and geranylgeranyl transferase-1 (GGT) inhibitory activities (IC50s of 250 nM and 520 nM for FT and GGT, respectively), mitigates KRAS resistance by preventing its membrane localization, effectively impeding mutant KRAS patient-derived pancreatic tumors. |
| Targets&IC50 | FT:250 nM , GGT:520 nM |
| In vitro | FGTI-2734 mesylate (3-30 μM;?72 hours) inhibits both protein prenylation of HDJ2, RAP1A, KRAS and NRAS. FGTI-2734 mesylate (1-30 μM; 72 hours) induces apoptosis in mutant KRAS-dependent, but not mutant KRAS- independent, human cancer cells. ??FGTI-2734 inhibits KRAS membrane localization in RAS-transformed murine NIH3T3 cells and in mutant KRAS human cancer cells. |
| In vivo | FGTI-2734 mesylate (intraperitoneally;?100 mg/kg/day for 18 to 25 days) only inhibits tumor growth in mutant KRAS-dependent tumors but not in mutant KRAS-independent tumors. |
| Alias | FGTI-2734 mesylate |
| Molecular Weight | 606.73 |
| Formula | C27H35FN6O5S2 |
| Cas No. | 2702297-24-1 |
| Relative Density. | no data available |
Storage & Solubility Information
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 75 mg/mL (123.61 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Keywords
Preview
Related Tags: buy FGTI-2734 mesylate (1247018-19-4 free base) | purchase FGTI-2734 mesylate (1247018-19-4 free base) | FGTI-2734 mesylate (1247018-19-4 free base) cost | order FGTI-2734 mesylate (1247018-19-4 free base) | FGTI-2734 mesylate (1247018-19-4 free base) chemical structure | FGTI-2734 mesylate (1247018-19-4 free base) in vivo | FGTI-2734 mesylate (1247018-19-4 free base) in vitro | FGTI-2734 mesylate (1247018-19-4 free base) formula | FGTI-2734 mesylate (1247018-19-4 free base) molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.